[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundacion Dexeus\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,69,93,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635739","ultra-rapid-blastocyst-vitrification-pilot-randomized-study-100635739",false,"NCT07556601","Ultra-rapid Blastocyst Vitrification: Pilot Randomized Study","Clinical Validation of Ultra-rapid Blastocyst Vitrification: a Randomized Pilot Study in Oocyte Donation Cycles","Inclusion Criteria:\n\n* Recipients of donor oocytes\n* Blastocysts suitable for cryopreservation\n\nExclusion Criteria:\n\n* Cycles involving PGT\n* Cycles not reaching blastocyst stage.","FEMALE","18 Years","50 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.",[27],"Infertility","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2026-06-01",{"date":36,"type":21},"2028-03",{"name":38,"class":39},"Fundacion Dexeus","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100574795","phase-4-intranasal-nafarelin-for-triggering-oocyte-maturation-100574795","NCT06763926","Intranasal Nafarelin For Triggering Oocyte Maturation","Intranasal Nafarelin Compared to Subcutaneous Triptorelin for Triggering Final Oocyte Maturation in Ovarian Stimulation: a Non-inferiority Randomised Controlled Clinical Trial","INFORM","Inclusion Criteria:\n\n* Women undergoing fertility preservation cycles with oocyte cryopreservation\n* Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s)\n* BMI 18 - 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to either of the study drugs\n* Hypopituitarism\n* Known pituitary tumour\n* Contraindication to intranasal medication administration\n* Previous poor response to agonist trigger","40 Years",{"count":51,"type":21},154,[53],"PHASE4","This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.",[56],"Fertility Preservation",[58,59],"IVF","GnRH agonist","NOT_YET_RECRUITING","2026-06-02",{"date":63,"type":32},"2026-06-04",{"date":65,"type":21},"2026-06-15",{"date":67,"type":21},"2028-01-15",{"name":38,"class":39},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":5},"100632548","ai-top-study-artificial-intelligence-for-trigger-optimization-100632548","NCT07515118","AI-TOP Study Artificial Intelligence for Trigger Optimization.","An Artificial Intelligence Based Approach for Selecting the Optimal Day for Triggering.","AI-TOP","Inclusion Criteria:\n\n* Undergoing COS for IVF with autologous oocytes, oocyte donation and elective fertility preservation with all monitoring USS (ultrasound scan) conducted at our centers.\n\nExclusion Criteria:\n\n* Medically indicated fertility preservation\n* Inability to attend clinic visits for monitoring.","42 Years",{"count":79,"type":21},644,[24],"To evaluate, in a randomized controlled trial, whether AI-guided monitoring and ovulation triggering leads to clinical outcomes comparable to those achieved through physician-led decision-making in patients undergoing ovarian stimulation for IVF.",[27,83,84],"Ovarian Stimulation","Artificial Intelligence","2026-04-21",{"date":87,"type":32},"2026-04-22",{"date":89,"type":32},"2026-04-08",{"date":91,"type":21},"2027-09",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100583442","intraoperative-ultrasound-in-bowel-deep-endometriosis-100583442","NCT06876376","Intraoperative Ultrasound in Bowel Deep Endometriosis","Intraoperative Transvaginal and Endorectal Ultrasound for the Assessment of Bowel Deep Infiltrating Endometriosis","Inclusion Criteria:\n\n* Preoperative sonographic and\u002For MRI findings suggestive of bowel DIE (uterosacral ligaments, posterior vaginal wall, parametrium, retrocervical area, rectovaginal septum, rectum, and\u002For sigmoid colon).\n* Scheduled for surgical treatment (laparoscopy or robot-assisted laparoscopy).\n* Planned postoperative follow-up for at least 12 months.\n* Written informed consent provided before surgery.\n\nExclusion Criteria:\n\n* Planned surgery for diagnostic purposes only.\n* Pregnancy at the time of enrollment.\n* Poor understanding of Spanish or English.",{"count":101,"type":21},200,"OBSERVATIONAL","This study investigates the use of intraoperative transvaginal (IOTVUS) and\u002For endorectal ultrasound (IOERUS) in the surgical treatment of bowel deep infiltrating endometriosis (DIE).",[105],"Deep Infiltrating Endometriosis With or Without Bowel Involvement",[107,108,109,110,111],"Endometriosis","Intraoperative Ultrasound","Ultrasound","surgery","minimally invasive surgery","2026-03-25",{"date":114,"type":32},"2026-03-30",{"date":116,"type":32},"2025-01-20",{"date":118,"type":21},"2027-06",{"name":38,"class":39},1,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":5},"100611588","phase-4-effect-of-semaglutide-on-embryo-quality-in-overweight-and-obese-patients-undergoing-in-vitro-fertilization-100611588","NCT07242534","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial","SEQ","Inclusion Criteria:\n\n* ≤ 38 years\n* AMH \\>= 1 ng\u002FmL or AFC \\>= 6\n* Body mass index (BMI) between 27 kg\u002Fm2 and 40 kg\u002Fm2\n* Scheduled for IVF with freeze-all strategy\n\nExclusion Criteria:\n\n* Severe male factor (sperm concentration \\\u003C5M\u002FmL)\n* Type 2 diabetes mellitus\n* Prior use of GLP-1 Ras within the past year\n* Uncontrolled thyroid disorders\n* Contraindications to IVF or semaglutide treatment\n* Patients with chronic inflammatory diseases\n* Family history of hereditary or chromosomal diseases\n* Use of glucocorticoids or immunosuppressants\n* PGT-A\n* Use of medications affecting metabolism or inflammation","38 Years",{"count":131,"type":21},62,[53],"This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.",[27,135],"Obesity",[135,137,138,58,139],"Overweight","GLP-1 receptor agonist","ART","2026-01-19",{"date":142,"type":32},"2026-01-21",{"date":140,"type":32},{"date":145,"type":21},"2027-05",{"name":38,"class":39},""]